These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11728268)

  • 1. Omapatrilat: a unique new agent for the treatment of cardiovascular disease.
    Nawarskas JJ; Anderson JR
    Heart Dis; 2000; 2(3):266-74. PubMed ID: 11728268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omapatrilat for the management of heart failure and hypertension.
    Husereau DR
    Issues Emerg Health Technol; 2001 Jun; (17):1-4. PubMed ID: 11776285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Omapatrilat--new drug for patients with hypertension and heart failure].
    Dzielska-Olczak M
    Pol Merkur Lekarski; 2005 Oct; 19(112):556-8. PubMed ID: 16379325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension.
    Ferrario CM; Smith RD; Brosnihan B; Chappell MC; Campese VM; Vesterqvist O; Liao WC; Ruddy MC; Grim CE
    Am J Hypertens; 2002 Jun; 15(6):557-64. PubMed ID: 12074359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic effect of combined treatment with omapatrilat and adrenomedullin on the progression of heart failure in rats.
    Nishikimi T; Mori Y; Ishimura K; Ishikawa Y; Koshikawa S; Akimoto K; Minamino N; Kangawa K; Matsuoka H
    Am J Hypertens; 2006 Oct; 19(10):1039-48. PubMed ID: 17027825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopeptidase inhibitors.
    Weber MA
    Lancet; 2001 Nov; 358(9292):1525-32. PubMed ID: 11705582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat.
    Loch D; Hoey A; Brown L
    Clin Exp Hypertens; 2006 Jul; 28(5):475-88. PubMed ID: 16820344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients.
    Campese VM; Lasseter KC; Ferrario CM; Smith WB; Ruddy MC; Grim CE; Smith RD; Vargas R; Habashy MF; Vesterqvist O; Delaney CL; Liao WC
    Hypertension; 2001 Dec; 38(6):1342-8. PubMed ID: 11751715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
    Grönholm T; Cheng ZJ; Palojoki E; Eriksson A; Bäcklund T; Vuolteenaho O; Finckenberg P; Laine M; Mervaala E; Tikkanen I
    Eur J Pharmacol; 2005 Sep; 519(3):267-76. PubMed ID: 16137672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antianginal efficacy of omapatrilat in patients with chronic angina pectoris.
    Chaitman BR; Ivleva AY; Ujda M; Lenis JH; Toth C; Stieber DM; Reisin LH; Pangerl AM; Friedman JB; Lawrence JH
    Am J Cardiol; 2005 Jun; 95(11):1283-9. PubMed ID: 15904630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Nawarskas J; Rajan V; Frishman WH
    Heart Dis; 2001; 3(6):378-85. PubMed ID: 11975822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension.
    Maniu CV; Meyer DM; Redfield MM
    Hypertension; 2002 Oct; 40(4):528-34. PubMed ID: 12364358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril.
    Trippodo NC; Fox M; Monticello TM; Panchal BC; Asaad MM
    J Cardiovasc Pharmacol; 1999 Dec; 34(6):782-90. PubMed ID: 10598120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of omapatrilat in low, normal, and high renin experimental hypertension.
    Trippodo NC; Robl JA; Asaad MM; Fox M; Panchal BC; Schaeffer TR
    Am J Hypertens; 1998 Mar; 11(3 Pt 1):363-72. PubMed ID: 9544878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
    Regamey F; Maillard M; Nussberger J; Brunner HR; Burnier M
    Hypertension; 2002 Sep; 40(3):266-72. PubMed ID: 12215465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
    Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
    J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure.
    McClean DR; Ikram H; Garlick AH; Richards AM; Nicholls MG; Crozier IG
    J Am Coll Cardiol; 2000 Aug; 36(2):479-86. PubMed ID: 10933361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging treatments for hypertension: potential role for vasopeptidase inhibition.
    Weber M
    Am J Hypertens; 1999 Nov; 12(11 Pt 2):139S-147S. PubMed ID: 10596765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.